PDI signs four-year deal with Novartis
Contract sales firm PDI signed a four-year agreement with Novartis to deploy a field force promoting Elidel, a second-line eczema treatment for patients older than 2 years, according to Kim Golodetz, a spokesperson for PDI.
The deal calls for deployment of “approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide,” a PDI statement said.
After losing contracts with GlaxoSmithKline and Sanofi-Aventis in 2006, PDI rebounded with a “top-five pharmaceutical company” contract in 2007.
In February, the company named Peter Tilles president of its TVG marketing research and consulting unit.